Ken Griffin 23and Me Holding Co. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$0.36 - $0.61 $10,260 - $17,385	28,500 Added 97.6%	57,700 $22,000
Q1 2024 May 15, 2024	SELL	$0.4 - $0.91 $59,480 - $135,317	-148,700 Reduced 83.59%	29,200 $15,000
Q4 2023 Feb 14, 2024	SELL	$0.71 - $0.97 $17,395 - $23,765	-24,500 Reduced 12.1%	177,900 $161,000
Q3 2023 Nov 14, 2023	SELL	$0.96 - $2.01 $38,304 - $80,198	-39,900 Reduced 16.47%	202,400 $198,000
Q2 2023 Aug 14, 2023	BUY	$1.59 - $2.29 $6,837 - $9,847	4,300 Added 1.81%	242,300 $424,000
Q1 2023 May 15, 2023	SELL	$2.05 - $2.87 $22,549 - $31,570	-11,000 Reduced 4.42%	238,000 $542,000
Q4 2022 Feb 14, 2023	BUY	$2.06 - $3.47 $51,088 - $86,056	24,800 Added 11.06%	249,000 $537,000
Q3 2022 Nov 14, 2022	SELL	$2.6 - $5.12 $104,260 - $205,312	-40,100 Reduced 15.17%	224,200 $641,000

159

100M

270K

349K

Ticker ME
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 259,768,000
Market Cap $80.5M
Description
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of pa...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.